S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

OSTX OS Therapies Incorporated

1.68

-0.02 (-1.18%)

25 Feb 2025 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Jan 2025 to Feb 2025

Click Here for more OS Therapies Charts.

OS Therapies (AMEX:OSTX)
Historical Stock Chart
From Feb 2024 to Feb 2025

Click Here for more OS Therapies Charts.

OS Therapies Incorporated News

OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms
Monday 24 February 2025 (13 hours ago) • Business Wire

OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2
Thursday 20 February 2025 (5 days ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Wednesday 19 February 2025 (6 days ago) • Edgar (US Regulatory)

Form 5 - Annual statement of changes in beneficial ownership of securities
Saturday 15 February 2025 (1 week ago) • Edgar (US Regulatory)

OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing
Friday 14 February 2025 (2 weeks ago) • Business Wire

Form PRE 14A - Other preliminary proxy statements
Saturday 8 February 2025 (2 weeks ago) • Edgar (US Regulatory)

OS Therapies Provides Corporate Update
Tuesday 4 February 2025 (3 weeks ago) • Business Wire

Form S-1 - General form for registration of securities under the Securities Act of 1933
Saturday 1 February 2025 (3 weeks ago) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline
Thursday 30 January 2025 (4 weeks ago) • Business Wire

Form 8-K - Current report
Thursday 30 January 2025 (4 weeks ago) • Edgar (US Regulatory)

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline
Thursday 30 January 2025 (4 weeks ago) • Business Wire

Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership
Saturday 18 January 2025 (1 month ago) • Edgar (US Regulatory)

More OS Therapies Incorporated News Articles

National Australia Bank

Verizon Communications

Sterling vs AUD

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions